INDIANOLA, Pa., May 4 /PRNewswire/ -- MEDRAD has installed its 5,000th Stellant(R) CT Injection System since the introduction of the product just three years ago, a pace of one new Stellant install somewhere in the world every five hours. This pace demonstrates MEDRAD’s leading role in improving cardiac CT imaging and attests to the clinical value of Stellant technology.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )
MEDRAD marked the milestone Stellant installation on May 3 at the Cardiovascular Institute of the South (CIS) Houma Clinic in Houma, La. CIS is expanding its cardiac CT practice with new 64-slice CT scanners. “We chose Stellant D for its DualFlow option that enables management of contrast enhancement in both sides of the heart,” said Ritchie Dupre, diagnostic services manager at CIS. DualFlow has been demonstrated to improve right coronary artery visualization and to reduce artifacts. (1,2)
“Stellant is a tremendous product that is changing the way clinicians are looking at the human heart,” said John Friel, MEDRAD president and CEO, who was on hand to celebrate the install. “The numerous Stellant installations are evidence of cardiac CT’s value as a diagnostic tool and the leading role that MEDRAD plays with this emerging technology.”
Even as current Stellant technology continues to prove its value, MEDRAD is preparing several enhancements to the product, including:
* SmartFlow -- shown as a works-in-progress at RSNA 2005, SmartFlow provides a suggested cardiac protocol based on the individual characteristics of each patient. This customization is intended to improve enhancement and promote more efficient use of contrast agent. * iFlow -- open source interface technology that enables communication between Stellant and the CT scanner. Event photos are available online: http://www.medrad.com/newsroom/stellant5000.html.
CIS is one of the nation’s most respected cardiovascular centers, consisting of cardiologists, cardiovascular surgeons and thoracic surgeons, representing nearly every specialty in heart and vascular medicine. CIS and its staff of more than 400 dedicated team members and 40 physicians provide comprehensive cardiovascular care at 10 locations throughout south Louisiana. For more information about CIS, please visit http://www.cardio.com.
MEDRAD INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD’s product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2005 revenues were $411 million. MEDRAD INC. is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company’s world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD INC. is a U.S. affiliate of Schering AG, Germany . For more information, visit MEDRAD’s website at http://www.medrad.com.
Cautionary Statement Regarding Forward-Looking Statements.
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD’s plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events, circumstances or otherwise.
(1) Becker, Christoph, M.D., University Hospitals, Munich-Grosharden, Germany. Stellant D with DualFlow Cardiac Case Study. MEDRAD, INC. publication, 2005. (2) Jensen, Corey T., M.D., et. al., Medical University of South Carolina (MUSC), Charleston, S.C. Dual Flow Contrast Injection for Coronary CTA Improves Visualization of the Right Heart. (independent study) MEDRAD, INC. publication, 2006.
Photo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comMEDRAD, INC.
CONTACT: Tony Maiore, Computed Tomography Business Unit, +1-412-767-2400ext. 3350, or amaiore@medrad.com, or Dan Dieter, Marketing Services,+1-412-767-2400 ext. 3726, or ddieter@medrad.com, both of MEDRAD INC.
